HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN SUBSCRIBE JOIN FREE
LOADING
Price Investing Group
← Back to Research Watchlist
MDGL
Madrigal Pharmaceuticals Inc
Healthcare Biotechnology · Pennsylvania, USA · Reports in usd
Market Cap: $11.31B
Market Cap
$11.31B
Enterprise Val
$10.84B
P/E Ratio
-36.56
P/B Ratio
20.81
Trailing PEG (1Y)
-1.49
As Of
Jul 29, 2026

Overview & Key Metrics

Reporting period: Mar 31, 2026 · Q1 2026
Book Value$543.5M
Gross Margin91.38%
Profit Margin91.38%
Return on Equity-50.15%
Return on Assets-25.44%
Current Ratio3.50
Debt/Equity0.64
LT Debt/Equity0.64
Revenue Per Share13.57

Income Statement

Mar 31, 2026
Revenue$311.3M
Cost of Revenue$26.8M
Gross Profit$284.5M
R&D$108.7M
SG&A$268.5M
Operating Expenses$377.2M
Operating Income-$92.7M
Interest Expense$7.8M
Tax Expense$0.00
Net Income-$94.4M
EPS (Basic)$-3.25
EPS (Diluted)$-3.25
EBIT-$86.6M
EBITDA-$85.8M
Consolidated Income-$94.4M
Non-Controlling Interests$0.00

Balance Sheet

Mar 31, 2026
Cash & Equivalents$232.2M
Accounts Receivable$187.4M
Inventory$112.1M
Current Assets$1.18B
LT Investments$0.00
Property, Plant & Equipment$14.2M
Intangibles$7.3M
Non-Current Assets$45.0M
Total Assets$1.23B
Accounts Payable$60.8M
Current Debt$1.7M
Current Liabilities$338.3M
LT Debt$345.6M
Non-Current Liabilities$345.6M
Total Liabilities$683.9M
Total Debt$347.3M
Retained Earnings-$2.18B
Shareholder Equity$543.5M
Shares Outstanding22,939,969

Cash Flow Statement

Mar 31, 2026
Operating Cash Flow-$167.4M
Investing Cash Flow$192.2M
Financing Cash Flow$2.3M
CapEx-$3.8M
Free Cash Flow-$171.3M
Depreciation & Amort.$794.0K
Stock-Based Comp$34.0M
Acquisitions / Disposals$0.00
Investment Activity$196.0M
Debt Issued/Repaid$0.00
Equity Issued/Repaid$2.3M
Dividends Paid$0.00
Net Change in Cash$28.4M
Data cached · Meta cache · Daily cache · Statements cache · TTL 24h